ResMed (RMD) Beats Q4 Earnings and Revenue Estimates

Core Viewpoint - ResMed reported quarterly earnings of $2.08 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and showing a significant increase from $1.60 per share a year ago, indicating strong financial performance [1][2]. Financial Performance - The company achieved revenues of $1.22 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.73% and up from $1.12 billion year-over-year [2]. - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating a strong operational performance [2]. Stock Performance - ResMed shares have increased approximately 24% since the beginning of the year, outperforming the S&P 500's gain of 15.8% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.06 on revenues of $1.19 billion, while for the current fiscal year, the estimate is $8.71 on revenues of $5.01 billion [7]. - The outlook for the Medical - Products industry, where ResMed operates, is favorable, ranking in the top 36% of over 250 Zacks industries, which historically outperform the bottom half by more than 2 to 1 [8].